Polar Capital Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Polar Capital Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-250,000	Closed	-$4.71M	–	287
2023 Q1	$4.71M	Sell	250,000 -250,000	-50%	-$4.76M	0.03%	237
2022 Q4	$7.96M	Hold	500,000	–	–	0.06%	210
2022 Q3	$8.18M	Buy	+500,000	New	+$8.1M	0.05%	207
2021 Q2	–	Sell	-60,879	Closed	-$1.57M	–	351
2021 Q1	$1.57M	Sell	60,879 -101,837	-63%	-$4.48M	0.01%	279
2020 Q4	$8.7M	Buy	+162,716	New	+$8.08M	0.05%	220

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Polar Capital Holdings's ACAD Position: Q2 2023 in Review

Polar Capital Holdings sold out of Acadia Pharmaceuticals (ACAD) in Q2 2023, closing a stake of 250,000 shares — an estimated $4.71M sold.

Polar Capital Holdings first reported a position in ACAD in Q4 2020 and held it in 5 quarters. The position peaked at $8.7M in Q4 2020. 236 funds tracked by Wall St. Rank hold ACAD as of Q2 2023.

Polar Capital Holdings reported no remaining Acadia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Polar Capital Holdings sold 250,000 Acadia Pharmaceuticals shares in Q2 2023, an estimated $4.71M.
Polar Capital Holdings first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 5 quarters.
Polar Capital Holdings's Acadia Pharmaceuticals position peaked at $8.7M in Q4 2020.
236 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2023.

Based on Polar Capital Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.